IVA
NASDAQ
$4.42
Inventiva (IVA)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $15.13 (+242.70%)
Market Cap
$655M
EPS 5Y CAGR
+24.75%
FCF 5Y CAGR
+20.62%
Free Cash Flow Yield
-24.18%
Price Chart
Valuation
Market Cap$655M
P/S73.66
P/B2.10
Profitability
Total Revenue (TTM)$19M
Gross Profit (TTM)$7.94M
EBITDA-$453M
Operating Margin-992%
EPS-$6.78
Financial Health
Debt-to-Equity-611.3%
Free Cash Flow Yield-24.18%
Growth & Risk
EPS 5Y CAGR+24.75%
Revenue 5Y CAGR+4.71%
FCF 5Y CAGR+20.62%
Beta (5Y)0.79
Sharpe Ratio0.74